Prot #MK4830-002-02: A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer

Project: Research project

Project Details

StatusActive
Effective start/end date10/27/2210/27/25

Funding

  • Merck Sharp & Dohme LLC (Prot #MK4830-002-02)